Barry E. Storer

This story is part of the Forty for Forty Project: 40 outings in 40 weeks to celebrate the 40th anniversary of the Chelan-Douglas Land Trust. My first volunteer work with the Chelan-Douglas Land Trust was in the autumn of 2013. Under the direction of Hanne Beener, who much later would become the Executive Director of the organization, we assembled at the Saddle Rock Trailhead and wielded grub hoes and pick mattocks to decommission undesirable user-made trails.

To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Figure 1 Cumulative incidence rate of hospital admission. Figure 2 Reasons for hospital admissions in the first 100 days after HCT. Figure 3 Cumulative incidence rates. (A) Relapse-related mortality. NRM among hospitalized and nonhospitalized patients for (B) all, (C) unrelated, and (D) related patients.

Summary Background Acute graft-versus-host-disease (GVHD) after non-myeloablative human leucocyte antigen (HLA)-matched, unrelated donor, allogeneic haemopoietic stem cell transplantation (HSCT) is associated with considerable morbidity and mortality. This trial aimed to evaluate the efficacy of adding sirolimus to the standard cyclosporine and mycophenolate mofetil prophylaxis therapy for preventing acute GVHD in this setting.